Recent Updates
Recently added Catalysts

Bon Natural Life Limited

BONFDA catalysts, PDUFA dates & pipeline intelligence
$1.04
▼ -0.01 · -0.5%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BON financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.9552W HIGH $1.94
Volume
83.54 K
Value Traded
-
Short % Float
0.23%
Days to Cover
1.1
-5.02%Week
-8.35%1 Month
-8.35%3 Month
-17.73%6 Month
-99.92%5 Year
-99.92%All Time

Cash Data

Unlock BON cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.49 M
EPS (TTM)
-0.23
P/E Ratio
-
Ent. Value
16.79 M
Total Shares
8.13 M
Float Shares
6.01 M
Insiders
26.47%
Institutions
0.14%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every BON catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BON Catalyst Timeline

Dated clinical, regulatory and corporate events for Bon Natural Life Limited

Catalyst Timeline

Dated clinical, regulatory & corporate events for Bon Natural Life Limited

73Total events
0Upcoming
18Tier-1 (high impact)
2021 to 2026Coverage

Event history 50

▲Preclinical PoCPreclinical
Completed sample development and preliminary internal performance evaluations of AI-powered flexible bio-electronic mask with apple polyphenols
anti-agingsource ↗
▲Partnership / LicenseCorporate
Cooperation Framework Agreement with Tigerbone Group
▲Partnership / LicenseCorporate
BON and Chang'an Pilot establish Joint Laboratory for Natural Ingredients and Bio-Manufacturing
▲Product LaunchPost-Market
Launch of kombucha-inspired product
▲Partnership / LicenseCorporate
Non-exclusive strategic sales agreement with Qingshengyuan
▲Partnership / LicenseCorporate
Non-exclusive cooperation agreement with Beijing Huahai Keyuan for second-generation tea pigment digestive health products in Greater China
digestive healthsource ↗
▲Partnership / LicenseCorporate
Non-exclusive cooperation agreement with Beijing Huahai Keyuan for second-generation Apple Series health products
weight management and metabolic healthsource ↗
▲Preclinical PoCPreclinical
Identification of natural polyphenolic compounds from tea with weight-management activity in preliminary animal studies
weight managementsource ↗
▲Partnership / LicenseCorporate
Non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co., Ltd for weight loss products
weight losssource ↗
▲Partnership / LicenseCorporate
Non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co., Ltd. for natural prebiotic series products
gut healthsource ↗
Unlock the full BON catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BON actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all BON historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the BON pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BON program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every BON trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BON insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full BON insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in BON for Q3 2026.
Unlock every fund holding BON
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BON
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BON ownership
Insider and institutional ownership, quarter by quarter.

BON Short Interest

Shares sold short, counted twice a month.

0.23%
Short % of Float
of tradable shares sold short
13.6K
Shares Sold Short
-14.2% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
12.4K
Avg Daily Volume
the average used for days to cover
Unlock BON short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BON option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BON option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BON options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BON ranks across every disease it competes in

Competitive Position is a premium feature
See how BON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BON News

BON
Nov 20, 2026
BONGeneral
▼ -0.5%today

BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation

Bon Natural Life Limited announced the establishment of the BON Joint Lab with China Oat Group to advance biomanufacturing of natural ingredients. The lab will focus on AI-driven technologies and developing standards for oat-derived products. This collaboration aims to address supply challenges and enhance market potential for natural health products.

Read more →
BON
Mar 31, 2026
BONGeneral

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

Bon Natural Life Limited has announced a strategic partnership with Tigerbone Group to enhance collaboration in traditional Chinese medicine and life sciences. The agreement includes the formation of the 'BON Cooperation and Development Committee' to drive innovation and product development. This partnership aims to consolidate resources and leverage complementary strengths for global growth.

Read more →
BON
Feb 19, 2026
BONGeneral

BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

Bon Natural Life Limited has announced the successful development of a premium anti-aging bio-electronic facial mask using apple polyphenols and advanced AI-enabled technology. Initial internal evaluations show that the mask exceeds performance benchmarks for skin appearance and firmness. The company is moving towards third-party clinical testing and plans to optimize large-scale manufacturing. With the anti-aging market exceeding $100 billion, BON aims to position itself as a leader in this emerging segment.

Read more →
BON
Feb 17, 2026
BONGeneral

BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

Bon Natural Life Limited has launched the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing in collaboration with Chang'an Pilot. This facility aims to enhance the research and development of bio-manufactured natural ingredients for functional foods and personal care products. The initiative is expected to improve production efficiency and sustainability through innovative technologies.

Read more →
BON
Feb 17, 2026
BONGeneral

Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

Bon Natural Life Limited has partnered with Chang'an Pilot to launch a Joint Laboratory for Natural Ingredients and Bio-Manufacturing in Xi'an, China, as announced on February 17, 2026. This collaboration aims to enhance research and development of bio-manufactured natural ingredients for functional foods and personal care products. The laboratory will utilize fermentation-based biosynthesis and artificial intelligence to optimize production processes, providing a more sustainable alternative to traditional methods. The partnership is expected to advance BON's growth strategy and improve production efficiency.

Read more →
BON
Dec 10, 2025
BONGeneral
▲ +8.2%on this news

BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan

Bon Natural Life Limited has launched a new kombucha-inspired beverage and entered a $12 million strategic sales agreement with Shaanxi Qingshengyuan Health Industry Co., Ltd. The partnership aims to distribute BON's tea-pigment products across Greater China over the next 24 months. This move aligns with the growing consumer interest in natural ingredients and functional beverages.

Read more →
BON
Nov 25, 2025
BONGeneral

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

Bon Natural Life Limited has announced a cooperation agreement with Beijing Huahai Keyuan for the distribution of its second-generation tea pigment-based digestive health products in Greater China. The agreement, valued at US$26 million over 36 months, aims to leverage the growing demand for digestive wellness and blood-glucose management. BON's innovative tea pigments have shown significant improvements in health benefits, positioning the company for growth in the premium digestive health market.

Read more →
BON
Sep 29, 2025
BONGeneral

BON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of

BON Natural Life Limited released its condensed consolidated balance sheets for the period ending March 31, 2025. The company reported total assets of $71.58 million, reflecting a growth from $61.77 million at the end of the previous period. Notably, net income attributable to the company improved compared to the prior period. However, the company also faced a comprehensive loss, showcasing challenges in profitability despite asset growth.

Read more →
BON
Sep 9, 2025
BONGeneral
▼ -36.1%on this news

BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

Bon Natural Life Limited has announced a non-exclusive cooperation agreement worth $18 million with Beijing Huahai Keyuan Technology to distribute its innovative second-generation Apple Series health products in Greater China. This new product line boasts 80% higher bioactivity and aims to meet the growing demand in weight management and metabolic health. The company is optimistic about its market performance and potential revenue growth.

Read more →
BON
Sep 2, 2025
BONGeneral

BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

Bon Natural Life Limited has announced the identification of natural polyphenolic compounds from tea that show promise in weight management through its AI-powered R&D platform. Preliminary tests indicate these compounds outperform existing weight-managing drugs. With the global obesity crisis driving market growth, BON aims to capture a significant share of the weight management therapeutics market.

Read more →
BON
Aug 5, 2025
BONFDA Updates

BON Announces Reciept of Nasdaq Compliance Letter

Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2). The Nasdaq Hearings Panel confirmed this decision, and the compliance matter is now closed. The company will be subject to a one-year Discretionary Panel Monitor, ensuring ongoing compliance oversight.

Read more →
BON
Jul 30, 2025
BONGeneral

BON Launches AI-Powered New Drug Research and Development

Bon Natural Life Limited has launched an AI-driven drug research and development business, leveraging its library of natural compounds, particularly from Traditional Chinese Medicine. This initiative aims to enhance the efficiency and success rate of drug discovery by identifying promising lead compounds. CEO Yongwei Hu expressed optimism about achieving breakthroughs in pharmaceutical research through this strategic evolution.

Read more →
BON
Jul 21, 2025
BONGeneral
▼ -6%on this news

BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd

Bon Natural Life Limited has announced a $22 million distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. for its weight loss products. This non-exclusive agreement spans 36 months and allows Huahai Keyuan to distribute BON's innovative weight management line across China and Southeast Asia. The products are designed to facilitate weight management without requiring significant lifestyle changes.

Read more →
BON
Jul 14, 2025
BONFDA Updates

BON Announces Nasdaq Compliance

Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's continued listing requirements. The company received formal notice from the Nasdaq Hearings Panel confirming it met the Minimum Bid Price Requirement. BON will remain under a Discretionary Panel Monitor for one year to ensure ongoing compliance.

Read more →
BON
Jul 2, 2025
BONGeneral
▲ +18.7%on this news

Bon Announces Breakthrough Order for $16 Million Gut-Health Products

Bon Natural Life Limited has announced a $16 million distribution agreement with Beijing Huahai Keyuan Technology to market its new prebiotic products in China. This partnership is expected to enhance Bon's presence in the growing gut health market. The innovative product series features a unique 'Prebiotic + Postbiotic' complex aimed at improving gut microbiota health.

Read more →
BON
Jun 16, 2025
BONGeneral

Bon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.

Bon Natural Life Limited has announced a non-exclusive distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd. The agreement, valued at up to $18 million over 36 months, will see Merrill-Youli market and distribute Bon's Ambroxide and related fragrance compounds in the Asia-Pacific region. The partnership aims to strengthen Bon's position in the fragrance market, particularly in fabric applications, while also advancing the development of a biosynthetic alternative to Sclareol.

Read more →
BON
Jun 3, 2025
BONGeneral
▲ +6.9%on this news· ran to +22% by day 1

BON Announces Share Repurchase Program for up to US$1.0 Million

Bon Natural Life Limited has announced a share repurchase program allowing for the purchase of up to $1.0 million of its Class A ordinary shares. The program's execution will depend on various factors including market conditions and corporate liquidity. TradeUp Securities has been appointed as the exclusive agent for the repurchase. This initiative reflects the company's confidence in its financial stability.

Read more →
BON
May 22, 2025
BONGeneral
▲ +50%on this news

BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade

Bon Natural Life Limited has announced a sales cooperation agreement with Shanghai Risesun International Trade to market its tea pigment health products in China. The agreement, valued at $24 million over 24 months, aims to tap into the growing demand for digestive wellness and blood glucose regulation. CEO Hu Yongwei emphasized the partnership's potential to accelerate revenue growth and expand BON's market presence.

Read more →
BON
May 16, 2025
BONGeneral
▲ +22.5%on this news

BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

Bon Natural Life Limited (BON) has announced the launch of its patented postbiotic hypoglycemic ingredient product series and an exclusive cooperation agreement with Beijing Huahai Keyuan. The agreement, valued at 32 million USD, aims to enhance BON's presence in the global blood sugar health market. The new ingredient is designed to effectively regulate blood sugar levels, offering safety and convenience for users.

Read more →
BON
May 15, 2025
BONGeneral
▼ -13.2%on this newsshared move

Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split

Bon Natural Life Limited announced a 1-for-25 reverse stock split effective May 19, 2025, to comply with Nasdaq's minimum bid price requirement. The split will not affect shareholders' percentage interests. The company also increased its authorized share capital and adjusted the conversion rate for Class B shares. This decision was approved by shareholders at an extraordinary general meeting.

Read more →

About Bon Natural Life Limited

96 employees bnlus.com
BIOPHARMAWATCH ELITE
Trade the next BON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime